X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Capital good stocks lead the rally 
(Thu, 18 Apr 01:30 pm) 
 
Backed by strong buying sentiment, Indian share markets climbed higher in the post-noon trading session. Barring metal and IT, all the sectoral indices are trading positive. capital goods, consumer durables and banking stocks are the major gainers.

BSE-Sensex is up 149 points and NSE-Nifty is trading up 50 points. While BSE Mid Cap is up 0.4%, BSE Small Cap index is trading up by 0.3%. The rupee is trading at 54.0 to the US dollar.

According to the Commerce & Industry Ministry, the country's export turnover recorded a decline of 1.8% to $300.6 bn in FY13. Lower exports were due to fall in growth of engineering and textile sectors arising from slowdown in the global economy. Exports for FY13 were much lower than the export target of $360 bn set by the government for the year. The slump in exports has pushed up the trade deficit to $190.9 bn in FY13 from $183.4 bn in the previous year. With an aim to boost exports, the government has announced a number of steps. The government has extended the zero-duty Export Promotion Capital Goods (EPCG) Scheme beyond March 2013. This incentive programme would be available to all the sectors. Apart from this, the government has announced incentives for Special Economic Zones (SEZ's) to encourage exports.

Most of the Indian pharma stocks are trading in green with Wockhardt Ltd and Ranbaxy Laboratories being the leading gainers. Lupin Ltd (LUPL), announced that U.S Court of Appeals for the Federal Circuit has given verdict in the company's favour regarding the ongoing litigation on the Bayer's drug Yaz. Yaz is an oral contraceptive and Lupin is awaiting approval from USFDA (United States Food and Drug Administration). Lupin's generic Drospirenone and Ethinyl Estradiol Tablets (3 mg + 0.02 mg) is equivalent to Bayer AG's Yaz tablets. Reportedly, the total annual sales for branded and generic sales for the product stood at US$ 361 m. Lupin has already established portfolio in the oral contraceptive space. The approval and launch of Yaz generics in US market will be positive for the company. The stock of Lupin was trading up by 0.05%

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Capital good stocks lead the rally". Click here!

  
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 22, 2017 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS